http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007529550-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2005-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2007-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2007529550-A |
| titleOfInvention | How to treat alcoholism |
| abstract | In the treatment of alcohol addiction, joint treatment with active agents that can offset undesirable clinical signs that are undesirable for the treatment itself (eg, adverse clinical signs of negative drugs) greatly increases patient compliance. Increasing patient compliance also creates better success rates and reduces addiction or relapse. The present invention combines the use of opioid antagonists and at least one dopamine D2 partial agonist for the treatment of alcoholism. Preferred dopamine D2 partial agonists are aripiprazole and (−) 3- (3-hydroxyphenyl) -Nn-propylpiperidine [(−)-3PPP]. |
| priorityDate | 2004-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.